How can ebola be cured

For most people visiting countries in sub-Saharan Africa, the risk of exposure to the Ebola virus is minimal. People most at risk are those who care for infected people, such as aid workers, or those who handle their blood or body fluid, such as hospital workers, laboratory workers and family members.

The Foreign and Commonwealth Office also provides country by country advice for visitors , including the latest information on potential health risks. Diarrhoea , being sick, a rash, stomach pain and reduced kidney and liver function can follow. The infection may then cause internal bleeding as well as bleeding from the ears, eyes, nose or mouth. Get medical advice as soon as possible if you become ill while travelling abroad. It's extremely unlikely that you have Ebola, but it could be another serious condition such as cholera or malaria , so get help in case you need tests or treatment.

Sometimes a doctor may want to take a sample of your blood, urine or poo so it can be checked for infections. The Ebola virus disease is spread through contact with the blood, body fluids or organs of a person or animal with the infection. Ebola can not be caught through routine social contact, such as shaking hands, with people who do not have symptoms.

There's currently no licensed treatment or vaccine for Ebola virus disease, although vaccines and drug therapies are being developed and tested. Supportive Care Whether or not other treatments are available, basic interventions can significantly improve chances of survival when provided early.

These are referred to as supportive care, and include: Providing fluids and electrolytes body salts orally or through infusion into the vein intravenously. Using medication to support blood pressure, reduce vomiting and diarrhea, and to manage fever and pain.

Treating other infections, if they occur. Signs and Symptoms Diagnosis Information for Clinicians. Links with this icon indicate that you are leaving the CDC website.

The primary efficacy endpoint was day mortality. The primary analysis population was all patients who were randomized and concurrently eligible to receive either Inmazeb or the investigational control during the same time period of the trial. Of the patients who received Inmazeb, In the expanded access program, an additional patients received Inmazeb.

The most common symptoms experienced while receiving Inmazeb included: fever, chills, tachycardia fast heart rate , tachypnea fast breathing , and vomiting; however, these are also common symptoms of Ebola virus infection. Hypersensitivity, including infusion-related events, can occur in patients taking Inmazeb, and treatment should be discontinued in the event of a hypersensitivity reaction.

Inmazeb received an Orphan Drug designation for the treatment of Ebola virus infection. The Orphan Drug designation provides incentives to assist and encourage drug development for rare diseases.